Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of chemotherapy efficacy and toxicity of 5-Fluoruracil by coventional dosage and pharmcokinetic dosig for Chinese gastrointestinal patients.

ABSTRACT: Interventions: BSA:clinical experience;PK:clinical experience Primary outcome(s): CR/PR/PD Study Design: Randomized parallel controlled trial

DISEASE(S): Gastric Cancer / Colorectal Cancer

PROVIDER: 2675101 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Plasma Proteomic Biomarkers for Predicting Chemoradiation Response in Locally Advanced Cervical Cancer

Project description:A significant proportion of patients with locally advanced cervical cancer (LACC) experience treatment failure following concurrent chemoradiation therapy (CRT). Identifying patients unlikely to respond to CRT could inform personalized treatment strategies. In this study, we evaluated plasma proteomic profiles in 39 LACC patients stratified by CRT response: complete response (CR), partial response (PR), and progressive disease (PD). Using nano-liquid chromatography tandem mass spectrometry with data-independent acquisition (nano-LC MS/MS-DIA), we identified 507 protein groups, of which 407 were consistently detected in more than 50% of samples. Differential expression analysis revealed eight proteins significantly downregulated in non-responders, all of which are involved in inflammatory response pathways. Further subclass analysis demonstrated distinct proteomic dysregulation in PR patients compared to both CR and PD groups, with enrichment of pathways related to complement activation, NF-κB signaling, and lipid metabolism. Targeted validation using parallel reaction monitoring (PRM) confirmed a panel of 11 proteins that robustly distinguished PR from CR, yielding an area under the curve (AUC) of 0.862 (95% CI: 0.793–0.921). Integration with tumor RNA-seq data from The Cancer Genome Atlas (TCGA) revealed coordinated dysregulation in pathways involving HIF-1 signaling, proteoglycan and choline metabolism, PI3K-Akt signaling, and the complement and coagulation cascade. These findings suggest that baseline plasma protein profiles reflect underlying systemic inflammation and metabolic status, offering potential utility in predicting CRT responsiveness in LACC.

2025-11-03 | PXD064941 | JPOST Repository

Transplanted human organoids empower PK/PD assessment of drug candidate for the clinic

Project description:Pharmacokinetic/pharmacodynamic (PK/PD) studies are an essential component of pre-clinical drug discovery. Current best approaches for PK/PD studies, including the analysis of novel kidney disease targeting therapeutic agents, are limited to animal models with unclear translatability to the human condition. To address this challenge, we developed a novel approach for PK/PD studies using transplanted human kidney organoids. We performed PK studies with GFB-887, an investigational new drug now in Phase 2 trials. Orally dosed GFB-887 to athymic rats that had undergone organoid transplantation resulted in measurable drug exposure in human transplanted organoids. Importantly, we established the efficacy of orally dosed GFB-887 in PD studies, where quantitative analysis showed significant protection of kidney filter cells in human organoids and endogenous rat host kidneys. This widely applicable approach demonstrates, for the first time, feasibility of using transplanted human organoids in PK/PD studies, empowering organoids to revolutionize drug discovery.

2022-06-14 | GSE165104 | GEO

Trancription profling of In-transit extremity melanoma II lesions

Project description:An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with melphalan in the setting of isolated limb infusion Gene expression profiles were obtained from 52 lesions across 28 patients and evaluated for expression values that correlated with response to melphalan isolated limb infusion Chemotherapy response analysis: complete response - CR; partial response - PR; stable disease - SD; progressive disease - PD. 52 samples.

2010-03-09 | E-GEOD-19293 | biostudies-arrayexpress

In-transit extremity melanoma III

Project description:An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with melphalan in the setting of isolated limb infusion or isolated limb perfusion. Gene expression profiles were obtained from 21 lesions across 19 patients and evaluated for expression that correlated with response to melphalan isolated limb infusion. Chemotherapy response analysis: complete response - CR; partial response - PR; stable disease - SD; progressive disease - PD; not evaluable - n.e.

2011-12-22 | E-GEOD-34599 | biostudies-arrayexpress

Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection

Project description:Background: In multiple sclerosis (MS), immune up-regulation is coupled to subnormal immune response to interferon-β (IFN-β) and low serum IFN-β levels. The relationship between the defect in IFN signalling and acute and long-term effects of IFN-β on gene expression in MS is inadequately understood. Methods: We profiled IFN-β-induced transcriptome shifts, using high-resolution microarrays on 227 mononuclear cell samples from IFN-β-treated MS Complete Responders (CR) stable for five years, and stable and active Partial Responders (PR), stable and active untreated MS, and healthy controls. Findings: IFN-β injection induced short-term changes in 1,200 genes compared to baseline expression after 4-day IFN washout. Pre-injection after washout, and in response to IFN-β injections, PR more frequently had abnormal gene expression than CR. Surprisingly, short-term IFN-β induced little shift in Th1/Th17/Th2 gene expression, but up-regulated immune-inhibitory genes (ILT, IDO1, PD-L1). Expression of 8,800 genes was dysregulated n therapy-naïve compared to IFN-β-treated patients. These long-term changes in protein-coding and long non-coding RNAs affect immunity, synaptic transmission, and CNS cell survival, and correct the disordered therapy-naïve transcriptome to near-normal. In keeping with its impact on clinical course and brain repair in MS, long-term IFN-β treatment reversed the overexpression of proinflammatory and MMP genes, while enhancing genes involved in the oligodendroglia-protective integrated stress response, neuroprotection, and immunoregulation. In the rectified long-term signature, 277 transcripts differed between stable PR and CR patients.

2019-09-27 | GSE138064 | GEO

Proteome characterization of the neoadjuvant clinical trial PROMIX

Project description:Proteome characterization of the neoadjuvant clinical trial PROMIX. https://www.clinicaltrials.gov/ct2/show/NCT00957125 Patients received six rounds of chemotherapy with epirubicin and docetaxel, and if PR or PD after the second course, bevacizumab.

2024-03-19 | PXD039529 | JPOST Repository

mRNA expression profiles analysis of crocin mitigated triptolide-induced toxicity in mouse liver tissues

Project description:Clinical use of triptolide (TP) is restricted due to severe toxicity. This study assessed the protective effect of crocin (CR) as a natural antioxidant against TP-induced toxicity. Mouse Liver tissues were selected from the Control, MTP, and MTP+CR groups for transcriptome studies.

2022-05-06 | GSE202175 | GEO

Dayneka1993 - Theophylline-like 2-compartment PK with indirect PD response

Project description:Two-compartment PK model with Michaelis-Menten clearance and indirect PD response (Model IV). Theophylline-like diagnostic benchmark; not fitted to clinical data.

2026-06-27 | MODEL2605260001 | BioModels

Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary or secondary liver cancer

Project description:Primary objectives: Phase 1:• To characterize the safety and tolerability of GNS561• To identify the recommended Phase 2 dose (RD) • To characterize the PK of GNS561 Phase 2a:• To characterize the safety and tolerability of GNS561 • To identify evidence of antitumor activity (tumor control rate : overall response rate + SD by RECIST 1.1) Primary endpoints: Safety:• Incidence and nature of DLTs by dose level during the 4 week dose escalation phase• Incidence, nature, and severity of adverse events• Change in vital signs, clinical laboratory (chemistry and hematology) values, urinalysis, electrocardiogram (ECGs) Efficacy:• Response rate (CR+ PR) • Disease control rate (CR+PR+SD)• Progression free survival Pharmacokinetics:• GNS561 PK over first 48 hours following first and repeated dose in Cycle 1 and Cycle 2

| 2537358 | ecrin-mdr-crc

Effect of intestinal microbiome diversity on the efficacy and survival of chemotherapy for advanced non-small cell lung cancer

Project description:Interventions: Response Group:none;None Response Group:Nil Primary outcome(s): CR;PR;SD;PD;PFS;OS;Gut microbiome;Fecal metabolomics;Immune factor Study Design: Factorial

| 2689133 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data